Composition for diagnosing or predicting metabolic syndrome

• Main Authors: LEE KYOUNG RYUL, PARK JI MYEONG, KIM SEOL A, LEE SANG HOO, AHN JIN WOO, KIM JU HOON, KIM YE JIN
• Format: Patent
• Language: English; Korean
• Published: 20.08.2021
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; VINEGAR; WINE

The present invention relates to a composition for diagnosis or prediction of a metabolic syndrome, and more specifically, to single nucleotide polymorphism (SNP) that can predict a metabolic syndrome derived through a genome wide association study (GWAS). By using an SNP marker derived by the present invention, a metabolic syndrome can be diagnosed or predicted, and blood mercury levels can be predicted, so that patients with metabolic syndrome due to mercury accumulation can be effectively diagnosed and managed. On the basis of these effects, the present invention can be widely used in the pharmaceutical industry and the like. 본 발명은 대사증후군 진단 또는 예측용 조성물에 관한 것으로, 보다 상세하게는 GWAS(Genome wide association study)를 통해 도출한 대사증후군을 예측할 수 있는 단일염기 다형성(SNP, single nucleotide polymorphism)에 관한 것이다. 본 발명에 의해 도출된 SNP 마커를 이용하면, 대사증후군을 진단 또는 예측할 수 있으며, 혈중 수은 수준을 예측할 수 있어 수은 축적에 의한 대사증후군 환자를 효과적으로 진단, 관리할 수 있다. 이러한 효과를 기초로 본 발명은 의약업계 등에서 널리 활용될 수 있다.